| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Decision-making Tool for a Costly Innovative Technology: The Case of Carbon Ion Radiotherapy |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
41 |
| A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
| A cost analysis of complex radiotherapy for patients with head and neck cancer |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
41 |
| A cost-analysis of image-guided radiation therapy (IGRT) in prostate cancer: results from a phase III clinical trial |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
46 |
| A cost-analysis of stereotactic radiotherapy in lung cancer |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
21 |
| A cost-consequence analysis of hepatitis B screening in an immigrant population |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
| A cost-effectiveness analysis of a 6-month physical activity program versus usual dietary care during adjuvant chemotherapy in breast cancer: An economic evaluation of the PASAPAS trial |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
57 |
| A cost-effectiveness analysis of the ZIRA test in breast cancer |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
40 |
| A literature review to identify factors that determine policies for influenza vaccination |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
| A model to calculate treatment cost per protocol for light ion facility radiotherapy projects in Europe |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
| A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study) |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
30 |
| Adherence to practice guidelines for the management of patients with sarcoma: A cost-effectiveness assessment in two European regions |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
24 |
| Analyse des corrélations entre informatisation et performance des établissements de santé |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
25 |
| Apport de la génomique dans la médecine de demain, applications cliniques et enjeux |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
52 |
| Apports de l'évaluation médico-économique pour la décision publique en santé |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
22 |
| Apports de l'évaluation économique et de l'analyse d'impact budgétaire pour la décision publique en santé: l'exemple du cancer du sein |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
| Assessing the generalisability of cost evaluation results using the euclidean metric and principal components analysis: Lesson from a high-cost innovation in oncology |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
| Assessment of a self-administered questionnaire identifying occupational exposures among lung cancer patients |
0 |
0 |
1 |
15 |
1 |
2 |
12 |
66 |
| Being Treated In Higher Volume Hospitals Leads To Longer Progression-Free Survival For Epithelial Ovarian Carcinoma Patients in the Rhone-Alpes region of France |
0 |
0 |
0 |
13 |
0 |
0 |
2 |
42 |
| Challenges in the value assessment, Pricing, and funding of targeted combination therapies in oncology |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
36 |
| Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health |
0 |
0 |
1 |
2 |
0 |
0 |
7 |
17 |
| Chronic Low-Dose Exposure to Xenoestrogen Ambient Air Pollutants and Breast Cancer Risk: XENAIR Protocol for a Case-Control Study Nested Within the French E3N Cohort |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
9 |
| Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score–Weighted Analysis |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
18 |
| Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
| Comprendre les analyses médico-économiques: intervention didactique à l'intention des cliniciens |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
22 |
| Conformity with clinical practice guidelines for management of patients with sarcoma: a cost-effectiveness assessment in two European regions |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
| Connected device and therapeutic patient education to promote physical activity among women with localised breast cancer (DISCO trial): protocol for a multicentre 2×2 factorial randomised controlled trial |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
5 |
| Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
32 |
| Cost comparison of two surgical strategies in the treatment of breast cancer: Sentinel lymph node biopsy versus axillary lymph node dissection |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
12 |
| Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
| Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
41 |
| Cost of physical activity intervention during adjuvant chemotherapy in breast cancer: results of the randomized trial PASAPAS |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
16 |
| Cost of prostate image-guided radiation therapy: Results of a randomized trial |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
| Cost of radiotherapy: what is the quality of the evidence found? Critical quality appraisal of studies estimating cost of radiotherapy |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
| Cost-Effectiveness Of Treatments For Mild-To-Moderate Obstructive Sleep Apnea In France |
0 |
0 |
0 |
18 |
0 |
0 |
2 |
50 |
| Cost-effectiveness analysis of compliance with clinical guidelines for sarcoma management |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
13 |
| Cost-effectiveness analysis: an interdisciplinary research and methodological perspective |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
21 |
| Cost-effectiveness analysis: methods and applications in oncology |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
23 |
| Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
26 |
| Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
31 |
| Cost-effectiveness of a Genetic Test for Breast Cancer Risk - Letter |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
13 |
| Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
14 |
| Cost-utility analyses of interventions for informal caregivers: A systemic and critical review |
0 |
0 |
0 |
0 |
0 |
3 |
4 |
31 |
| Costi del tratamento |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
| Costs and compliance with clinical practice guidelines: A pilot study for initial sarcoma treatment |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
| Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
| Counterfactual approach with survival or time to event outcomes: An application to an exhaustive cohort of Epithelial Ovarian Carcinoma in the Rhône-Alps region of France |
0 |
0 |
0 |
9 |
0 |
0 |
1 |
53 |
| Counterfactual approach with survival or time to event outcomes: An application to an exhaustive cohort of Epithelial Ovarian Carcinoma in the Rhône-Alps region of France |
0 |
0 |
0 |
17 |
0 |
0 |
2 |
59 |
| Coût du programme d’éducation thérapeutique « Mieux manger, mieux bouger à l’aide de l’éducation nutritionnelle » chez les patientes atteintes d’un cancer du sein |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
| Curiethérapie: valorisation et aspects médico-économiques |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
18 |
| Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
27 |
| Determinants of the need for respite according to the characteristics of informal carers of elderly people at home: results from the 2015 French national survey |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
9 |
| Development of Seasonal Influenza Vaccination Recommendations: Relevance and Influence of the Evidence on the Decision-Making Process in France and the Netherlands |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
| Discordant diagnoses in sarcoma, GIST and desmoide tumour in France: results from the network RREPS |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
| Does adoption of electronic health records improve organizational performances of hospital surgical units? Results from the French e-SI (PREPS-SIPS) study |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
20 |
| Does adoption of electronic health records improve the quality of care management in France? Results from the French e-SI (PREPS-SIPS) study |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
| Does adoption of electronic heath record improve the quality of care management? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
| Does adoption of electronic records improve organizational performances of hospital surgical units? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
| Dossier Patient Informatisé: quel impact sur la performance des établissements de santé en France ? |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
51 |
| Economic burden of seasonal influenza B in France during winter 2010-2011 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
| Economic burden of seasonal influenza B in France during winter 2010-2011 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
| Economic burden of seasonal influenza B in France during winter 2010-2011 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
| Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
| Evaluation économique prospective de la radiothérapie guidée par l'image des cancers de la prostate dans le cadre du programme national de Soutien aux Thérapeutiques Innovantes et Coûteuses |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
27 |
| Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
23 |
| Financial impact of innovation in Oncology |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
12 |
| General Practitioners Perceptions About Financial and Non-Financial Incentives to Improve Influenza Vaccination Coverage Rates In France |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
| Guide méthodologique sur le calcul et l’analyse des coûts hospitaliers |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
45 |
| Guide méthodologique sur le costing à l’Hôpital |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
20 |
| Health Information System Adoption And Hospital Accreditation Decisions In France: Results From The E-SI (PREPS-SIPS) Study |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
21 |
| How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance? |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
8 |
| Impact d’une centralisation des soins en termes d’accès aux soins pour les cancers de l’ovaire et cancers du sein en France: une simulation à partir des données médico-administratives |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
| Impact financier de l’innovation en oncologie |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
11 |
| Impact of Electronic Health Records on the Hospital Bed Occupancy Rates in Surgical Units in France: Results from the E-SI (PREPS-SIPS) Study |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
17 |
| Impact of Electronic Health Records on the Hospital Bed Occupancy Rates in Surgical Units in France: Results from the E-SI (PREPS-SIPS) Study |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
28 |
| Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments |
0 |
0 |
0 |
0 |
2 |
2 |
3 |
17 |
| Impact of chemotherapy prescriptions and costs on survival in advanced or metastatic NSCLC: a single-institution study using an instrumental variables approach |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
| Impact of health information systems on hospital bed occupancy rates in French hospitals: results from the e-SI (PREPS-SIPS) study |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
11 |
| In Reply to Escande et al |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
| In Reply to Fodor and Di Muzio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| In reply to Jean-François Daisne, Sandra Nuyts, Fréderic Duprez and Benoît Bihin |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
| In reply to Tallet et al |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
12 |
| Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
28 |
| Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
| Inégalités d'exposition aux agents cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
48 |
| Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
| Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: SUMER 2010 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
| Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: les enseignements de l'enquête SUMER |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Inégalités de l’exposition aux produits chimiques cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: les enseignements de l’enquête SUMER |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
| Inégalités d’exposition aux agents cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France |
0 |
0 |
0 |
5 |
0 |
0 |
2 |
63 |
| Is the Integrated Electronic Health Record Cost-Effective for a Cancer Consultation? Results from the E-SI (PREPS-SIPS) Study |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
29 |
| Les apports des concepts économiques "d'équipe" et de "groupe" pour l'évaluation des réseaux de soins |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Les fortes expositions aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) sont-elles l'apanage des emplois précaires et peu qualifiés ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Les impacts médico-économiques de l'évolution du parcours de soins en cancérologie |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
23 |
| Les évaluations de coûts en santé sont-elles transférables ? |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
92 |
| Les évaluations de coûts en santé sont-elles transférables ? |
0 |
0 |
0 |
3 |
0 |
0 |
1 |
97 |
| Les évaluations de coûts en santé sont-elles transférables ? Mesures et application à une innovation très coûteuse en cancérologie |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
12 |
| Light ion facility projects in Europe: methodological aspects for the calculation of the treatment cost per protocol |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
| Literature review of the decision-making determinants related to the influenza vaccination policy |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
128 |
| Literature review of the decision-‐making determinants related to the influenza vaccination policy |
0 |
0 |
0 |
7 |
0 |
0 |
2 |
36 |
| Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
| National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project |
0 |
0 |
0 |
1 |
0 |
1 |
2 |
14 |
| Optimisation du parcours de soins dans la prise en charge initiale des cancers épithéliaux ovariens en France |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
42 |
| Organisation et financement des soins: vers une inadéquation croissante ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
12 |
| Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
37 |
| Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients: a safe, accurate, and cost-saving procedure |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
19 |
| Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
34 |
| Radiotherapy costs: the good, the bad and the ugly |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
| Relationship between the development of electronic health records and hospital accreditation decisions in France: results from the E-SI (Preps-Sips) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
15 |
| Report of work package 6 “Health economics aspects” |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
| Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
28 |
| Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
317 |
| Systematic Screening for Occupational Exposures in Lung Cancer Patients: A Prospective French Cohort |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
| Système d'information et performance hospitalière |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
36 |
| The contribution of the simulation for innovative technologies: The case of the hadrontherapy |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
| The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
| The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
103 |
| The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
42 |
| The impact of CD34+ cell dose on the cost of HDT with PBSC transplantation in lymphomia |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
18 |
| The use of economic evaluations in health decision-making at the macro level: a literature review |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
18 |
| Toxicity and efficacy of cetuximab associated with several modalitiesof IMRT for locally advanced head and neck cancer |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
19 |
| Toxicité et qualité de vie comparées après curiethérapie par iode 125 et radiothérapie stéréotaxique des cancers prostatiques [Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers] |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
34 |
| Trajectoires optimales des patients évoluant vers la dépendance |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
9 |
| Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
22 |
| Transférabilité des évaluations de coûts en santé: analyse des facteurs de variabilité |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Trends in occupational disparities for exposure to carcinogenic, mutagenic and reprotoxic chemicals in France 2003–10 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
| Value based healthcare et donnée de vie réelles/SNDS en radiothérapie |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
| Varied exposure to carcinogenic, mutagenic, and reprotoxic (CMR) chemicals in occupational settings in France |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
23 |
| Vers une nécessaire harmonisation des évaluations de coûts en santé. L'exemple des intensifications thérapeutiques avec autogreffes de cellules souches du sang périphérique en France |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
23 |
| What Underlies The Observed Hospital Volume-Outcome Relationship? |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
16 |
| What underlies the observed hospital volume- outcome relationship? |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
2 |
| What underlies the observed hospital volume-outcome relationship? |
0 |
0 |
0 |
24 |
1 |
1 |
1 |
45 |
| Why should we focus on a structured model of secure digital exchanges to incorporate new documents in electronic patient records? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
| Éditorial |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
| Total Working Papers |
0 |
0 |
2 |
185 |
22 |
44 |
170 |
3,608 |
LogEc is hosted by the
Örebro University School of Business.